Priovant Therapeutics, Inc.
๐บ๐ธUnited States
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
Phase 2
Recruiting
- Conditions
- Cutaneous Sarcoidosis
- Interventions
- Drug: Oral BrepocitinibDrug: Oral Placebo
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06978725
- Locations
- ๐บ๐ธ
Clinical Trial Site, Madison, Wisconsin, United States
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06433999
- Locations
- ๐บ๐ธ
Clinical Trial Site, Scottsdale, Arizona, United States
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Phase 3
Recruiting
- Conditions
- Uveitis, IntermediateUveitisUveitis, Posterior
- Interventions
- Drug: Placebo PO QDDrug: Brepocitinib PO QD
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06431373
- Locations
- ๐บ๐ธ
Clinical Trial Site, Madison, Wisconsin, United States
๐บ๐ธNYU Langone Health, New York, New York, United States
A Study of Brepocitinib in Adults with Active Non-Infectious Non-Anterior Uveitis
Phase 2
Completed
- Conditions
- Non-infectious Pan UveitisNon-infectious Intermediate UveitisNon-infectious Posterior Uveitis
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05523765
- Locations
- ๐บ๐ธ
Clinical Trial Site, Salt Lake City, Utah, United States
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Priovant Therapeutics, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT05437263
- Locations
- ๐ฌ๐ง
Clinical Trial Site, Wolverhampton, United Kingdom
ยฉ Copyright 2025. All Rights Reserved by MedPath